Innovative Cellular Therapeutics Holdings Ltd 4
4 · Lyell Immunopharma, Inc. · Filed Jul 27, 2026
Research Summary
AI-generated summary of this filing
Lyell (LYEL) 10% Owner Transfers 38,500 Shares as Broker Commission
What Happened
Innovative Cellular Therapeutics Holdings Ltd, listed as a 10% owner of Lyell Immunopharma (LYEL), transferred 38,500 shares of Lyell common stock on July 27, 2026. The shares were reported at $0.00 per share (total reported value $0) and are described as a transfer used to pay a broker commission related to the first Development Milestone under a license agreement dated November 6, 2025. This is a disposition/transfer (transaction code J) rather than a market sale or purchase and does not necessarily indicate a change in sentiment by the holder.
Key Details
- Transaction date: 2026-07-27; reported as Other acquisition/disposition (Code J).
- Price: $0.00 per share; total reported proceeds $0 (transfer as broker commission).
- Shares transferred: 38,500.
- Shares beneficially owned immediately after the transfer: 2,818,980 (2,857,480 prior minus 38,500 transferred).
- Footnote: Transfer to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone under the Nov. 6, 2025 License Agreement.
- Filing appears timely (reporting date and filing date both 2026-07-27).
- Insider type: 10% owner (institutional/major holder), not an individual executive — different implications than executive insider trades.
Context
This was a stock transfer to cover broker commission tied to a contractual milestone payment, not a cash sale on the open market. Such transfers are often administrative/transactional and do not necessarily reflect the holder’s view of the company’s outlook. For retail investors, outright purchases by insiders can be more informative than routine transfers or commission payments.
Insider Transaction Report
- Other
Common Stock
[F1][F2]2026-07-27−38,500→ 2,818,980 total
Footnotes (2)
- [F1]Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
- [F2]Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred.